文献速递抗菌药物管理药物不良反应与药物警戒

革兰阴性杆菌对氨基糖苷类耐药的风险因素

Risk factors for development of aminoglycoside resistance among gram-negative rods.
PubMed 文献 · Am J Health Syst Pharm · 2019-01-01

该研究回顾性分析2011—2016年两家学术医院系统中12516例患者分离的26154株革兰阴性杆菌,分别分析庆大霉素/妥布霉素耐药(GTR-GNR)和阿米卡星耐药(AmR-GNR)的风险因素。多因素分析显示两种耐药模式的风险因素不同,基于风险预测模型构建的评分系统可指导经验性抗菌治疗。

要点

  • 30天内使用碳青霉烯类是GTR-GNR和AmR-GNR的共同风险因素。
  • 30天内使用氟喹诺酮类与GTR-GNR风险相关。
  • 囊性纤维化、男性、机械通气与AmR-GNR风险相关。

核心结论

  • 基于风险预测模型构建的评分系统可供临床医生用于指导革兰阴性杆菌感染的经验性抗菌治疗。

研究设计与样本

  • 回顾性分析2011—2016年两家学术医院系统中12516例患者分离的26154株革兰阴性杆菌,分别分析GTR-GNR和AmR-GNR耐药模式。

主要发现

  • 共分析26154株革兰阴性杆菌,其中GTR 6699株,AmR 2467株。
  • GTR-GNR多因素分析风险因素包括体重减轻、来自其他医疗或长期护理机构、血红蛋白<11 g/dL、30天内使用碳青霉烯类、30天内使用氟喹诺酮类(C统计量0.63)。
  • AmR-GNR多因素分析风险因素包括囊性纤维化诊断、男性、来自其他医疗或长期护理机构、本次住院培养前任何时间点机械通气、30天内使用碳青霉烯类、30天内使用抗MRSA药物(C统计量0.74)。
  • 多项式和有序模型显示两种耐药模式的风险因素存在显著差异。

关键数值与推荐

  • GTR-GNR风险预测模型C统计量为0.63。
  • AmR-GNR风险预测模型C统计量为0.74。

临床怎么用

  • 临床可应用基于风险预测模型构建的评分系统,指导革兰阴性杆菌感染的经验性抗菌治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Development of scoring systems to predict the risk of aminoglycoside resistance and to guide therapy is described. METHODS: Infections due to aminoglycoside-resistant gram-negative rods (AR-GNRs) are increasingly common and associated with adverse outcomes; selection of effective initial antibiotic therapy is necessary to reduce adverse consequences and shorten length of stay. To determine risk factors for AR-GNR recovery from culture, cases of GNR infection among patients admitted to 2 institutions in a major academic hospital system during the period 2011-2016 were retrospectively analyzed. Gentamicin and tobramycin resistance (GTR-GNR) and amikacin resistance (AmR-GNR) patterns were analyzed separately. A total of 26,154 GNR isolates from 12,516 patients were analyzed, 6,699 of which were GTR, and 2,467 of which were AmR. RESULTS: In multivariate analysis, risk factors for GTR-GNR were presence of weight loss, admission from another medical or long-term care facility, a hemoglobin level of <11 g/dL, receipt of any carbapenem in the prior 30 days, and receipt of any fluoroquinolone in the prior 30 days (C statistic, 0.63). Risk factors for AmR-GNR were diagnosis of cystic fibrosis, male gender, admission from another medical or long-term care facility, ventilation at any point prior to culture during the index hospitalization, receipt of any carbapenem in the prior 30 days, and receipt of any anti-MRSA agent in the prior 30 days (C statistic, 0.74). Multinomial and ordinal models demonstrated that the risk factors for the 2 resistance patterns differed significantly. CONCLUSION: A scoring system derived from the developed risk prediction models can be applied by providers to guide empirical antimicrobial therapy for treatment of GNR infections.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Richter SE, Miller L, Needleman J, et al. Risk factors for development of aminoglycoside resistance among gram-negative rods. Am J Health Syst Pharm. 2019. PMID: 31665763. doi:10.1093/ajhp/zxz201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。